Matthew Pauls's Net Worth

$6.81 Million

Estimate Recalculated Nov 1, 2024 10:13AM EST

Who is Matthew Pauls

Matthew Pauls has an estimated net worth of $6.81 Million. This is based on reported shares across multiple companies, which include INSMED Inc, Strongbridge Biopharma plc, Egalet Corp, Savara Inc, and SOLENO THERAPEUTICS INC.

SEC CIK

Matthew Pauls's CIK is 0001573429

Past Insider Trading and Trends

2021 was Matthew Pauls's most active year for acquiring shares with 13 total transactions. Matthew Pauls's most active month to acquire stocks was the month of November. 2020 was Matthew Pauls's most active year for disposing of shares, totalling 3 transactions. Matthew Pauls's most active month to dispose stocks was the month of November. 2014 saw Matthew Pauls paying a total of $992,100.00 for 60,000 shares, this is the most they've acquired in one year. In 2023 Matthew Pauls cashed out on 212,680 shares for a total of $883,976.40, their largest year based on trade value.

Loading...

Attention insiders:Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

INSMED Inc

Chief Commercial Officer
Updated Jun 04, 2014
Form 4
30.00K
$12.58
$377.40K
Jun 04, 2014
30.00K
Grant
Jun 02
Form 4
30.00K
$20.49
$614.70K
Jan 14, 2014
30.00K
Grant
Jan 10
Form 4
25.00K
May 28, 2013
325.00K
Grant
May 23
Form 4
300.00K
Apr 03, 2013
100.00K
Grant
Apr 01
Form 3
Apr 03, 2013
Showing 5 results

Strongbridge Biopharma plc

President & CEO
Updated Feb 22, 2019
Form 4
1,990.45%
450.00K
Feb 22, 2019
472.61K
Grant
Feb 20
Form 4
-43.48%
-17.39K
$6.60
-$114.79K
Feb 28, 2018
22.61K
Tax
Feb 26
Form 4
350.00K
Feb 06, 2018
350.00K
Grant
Feb 05
Form 3
Jan 02, 2018
40.00K
Showing 4 results

Egalet Corp

Investor
Updated May 21, 2020
Form 4
-100.00%
-26.95K
May 21, 2020
Disposition
May 20
Form 4/A
172.95%
11.53K
$1.75
$8.51K
Apr 28, 2020
18.20K
Options
Apr 23
Form 4
185.75%
12.38K
$1.75
$10.00K
Apr 24, 2020
19.05K
Options
Apr 23
Form 4
13.62K
Mar 05, 2020
13.62K
Grant
Mar 04
Form 4
20.00K
Apr 24, 2019
20.00K
Grant
Apr 23
Form 3
Feb 08, 2019
Showing 6 results

Savara Inc

CHIEF EXECUTIVE OFFICER
Updated Dec 29, 2023
Form 4
-7.43%
-103.00K
$4.71
-$395.90K
Dec 29, 2023
1.28M
Sale
Dec 28
Form 4
54.03%
565.32K
$4.45
-$488.08K
Dec 15, 2023
1.61M
Grant
Dec 14
Form 4
142.09%
1.02M
Dec 15, 2022
1.75M
Grant
Dec 13
Form 4
-7.95%
-62.32K
$1.24
-$77.27K
Jan 03, 2022
721.35K
Tax
Dec 31
Form 4
195.48%
750.00K
Dec 14, 2021
1.13M
Grant
Dec 14
Form 4
1.72%
6.50K
$1.06
$6.89K
Dec 08, 2021
383.67K
Purchase
Dec 08
Form 4
2.72%
10.00K
$1.10
$10.95K
Dec 02, 2021
377.17K
Purchase
Dec 02
Form 4
6.42%
22.15K
$1.10
$24.39K
Nov 22, 2021
367.17K
Purchase
Nov 18 - Nov 19
Form 4
8.46%
26.90K
$1.18
$31.87K
Aug 18, 2021
345.02K
Purchase
Aug 17 - Aug 18
Form 4
3.25%
10.00K
$1.63
$16.30K
May 24, 2021
318.12K
Purchase
May 21
Form 4
9.76%
27.40K
$1.82
$49.87K
Apr 19, 2021
308.12K
Purchase
ScheduledApr 19
Form 4
9.39%
24.10K
$2.07
$49.94K
Mar 22, 2021
280.72K
Purchase
ScheduledMar 22
Form 4
12.59%
28.70K
$1.74
$50.04K
Feb 23, 2021
256.62K
Purchase
ScheduledFeb 22
Form 4
500.00K
Dec 17, 2020
500.00K
Grant
Dec 16
Form 4
173,217.08%
1.13M
Sep 15, 2020
1.13M
Options
Apr 27 - Sep 15
Form 4
12.00K
Dec 26, 2019
12.00K
Grant
Dec 20
Form 4
12.00K
Dec 14, 2018
12.00K
Grant
Dec 13
Form 4
3.75K
May 26, 2017
3.75K
Grant
May 25
Form 4
45.53K
Jan 23, 2017
45.54K
Grant
Jan 23
Form 4
79.55K
Jun 17, 2016
79.55K
Grant
Jun 15
Form 4
102.58K
Nov 02, 2015
102.59K
Grant
Oct 29
Form 3
Nov 02, 2015
Showing 22 results

SOLENO THERAPEUTICS INC

Investor
Updated Jun 10, 2024
Form 4
6.50K
Jun 10, 2024
6.50K
Grant
Jun 06
Form 4
15.00K
Aug 16, 2023
15.00K
Grant
Aug 15
Form 3
Aug 16, 2023
Showing 3 results